Join the Oncology Voice Network. Join for Free
How to Leverage YOUR Unique Skills for Career Advantage
Medical Science Liaison personal branding unique skills multilingualism international experience medical affairs career proactive networking overcoming challenges career growth imposter syndrome

How to Leverage YOUR Unique Skills for Career Advantage


Share This Article


Summary

In this episode, Tom Caravela sits down with Hahn-Ey Lee to discuss the importance of leveraging unique skills to advance the career of a Medical Science Liaison (MSL). The conversation delves into the significance of personal branding and how MSLs can showcase their unique skills effectively. Hahn-Ey emphasizes the advantages of multilingualism and international experience, providing tips on tailoring resumes and interview responses to highlight these attributes. They explore strategies for overcoming humility in interviews, fostering proactive career growth, and developing unique skills while combating imposter syndrome. The episode concludes with insights on building resilience within medical affairs and expressions of appreciation.

Key Points

  • Embracing and leveraging unique skills and personal branding is crucial for MSLs to navigate their career paths effectively.
  • Multilingual abilities and international experiences can provide significant competitive advantages and broaden career opportunities in the pharmaceutical industry.
  • Resilience and proactive networking are essential for overcoming challenges and setbacks, enabling continuous growth and success in a medical affairs career.

Click for Source
Medical Science Liaison, personal branding, unique skills, multilingualism, international experience, medical affairs career, proactive networking, overcoming challenges, career growth, imposter syndrome

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Surround to Succeed: Building a Motivational Network
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

Surround to Succeed: Building a Motivational Network

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Explore OVN